Transcatheter aortic valve implantation (TAVI) is the primary therapeutic option for severe aortic stenosis that are inoperable or have high surgical risk.
Diffusion-weighted MRI studies demonstrates that after TAVI some silent embolic cerebral infarcts are present that lead to consecutive mental deterioration. Cerebral embolic protection (CEP) devices is used to reduce the risk of stroke, neurocognitive decline and dementia caused by brain emboli associated with cardiovascular procedures.
The global Cerebral Thrombectomy Systems market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Cerebral Thrombectomy Systems volume and value at global level, regional level and company level. From a global perspective, this report represents overall Cerebral Thrombectomy Systems market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
ohnson and Johnson
The Spectranetics Corporation
Segment by Regions
Segment by Type
Clarets Sentinel System
Keystone Hearts Triguard Device
Embrella Embolic Deflector
Segment by Application